Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.76 |
| ▸ | MAOA | P21397 | 3/20 | 0.76 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2185997 | 1.00 | MAOB (0.76) | MAOBMAOASCN9A | |
| SCHEMBL964395 | 1.00 | MAOB (0.76) | MAOBMAOASCN9A | |
| SCHEMBL31060850 | 1.00 | MAOB (0.76) | MAOBMAOASCN9A | |
| SCHEMBL2167372 | 0.97 | MAOB (0.71) | MAOBMAOASCN9A | |
| SCHEMBL2167382 | 0.97 | MAOB (0.71) | MAOBMAOASCN9A | |
| SCHEMBL966003 | 0.91 | MAOB (0.62) | MAOBMAOASCN9A | |
| SCHEMBL23440935 | 0.89 | MAOB (0.64) | MAOBMAOASCN9A | |
| SCHEMBL69031 | 0.89 | MAOB (0.60) | MAOBMAOASCN9A | |
| SCHEMBL8636505 | 0.88 | MAOB (0.59) | MAOBMAOASCN9A | |
| SCHEMBL7393828 | 0.87 | MAOB (0.58) | MAOBMAOASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222290-B1 | ALPHA-AMINOAMIDE DERIVATIVES FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | NEWRON PHARM SPA (IT) | 2021-06-16 | — | — | EP | claimed |
| US-8741957-B2 | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2014-06-03 | — | — | US | claimed |
| CN-102274517-A | Methods for treatment of parkinson's disease | — | 2011-12-14 | — | — | CN | claimed |
| US-20100267835-A1 | Methods of treating disorders of trigeminalvascular activation | NEWRON PHARMACEUTICALS SPA (IT) | 2010-10-21 | — | — | US | claimed |
| US-7709523-B2 | Alpha-aminoamide derivatives useful as antimigraine agents | NEWRON PHARMACEUTICALS SPA (IT) | 2010-05-04 | — | — | US | claimed |
| EP-2070526-A1 | \"Methods for treatment of Parkinson's disease\ | Newron Pharmaceuticals S.p.A. (IT) | 2009-06-17 | — | — | EP | claimed |
| EP-1585510-B1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTIMIGRAINE AGENTS | NEWRON PHARM SPA (IT) | 2007-12-05 | — | — | EP | claimed |
| US-20070093495-A1 | Methods for treatment of parkinson's disease | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-04-26 | — | — | US | claimed |
| CN-1771030-A | Methods of treating Parkinson's disease | NEWRON PHARMACEUTICALS INC (IT) | 2006-05-10 | — | — | CN | claimed |
| US-20060079570-A1 | Alpha-aminoamide derivatives useful as antimigraine agents | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2006-04-13 | — | — | US | claimed |
| EP-1585510-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTIMIGRAINE AGENTS | Newron Pharmaceuticals S.p.A. (IT) | 2005-10-19 | — | — | EP | claimed |
| WO-2004062655-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTIMIGRAINE AGENTS | NEWRON PHARMACEUTICALS SPA (IT) | 2004-07-29 | — | — | WO | claimed |
| EP-1438956-A1 | Alpha-aminoamide derivatives useful as antimigraine agents | Newron Pharmaceuticals S.p.A. (IT) | 2004-07-21 | — | — | EP | claimed |
| EP-2222290-B1 | ALPHA-AMINOAMIDE DERIVATIVES FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | NEWRON PHARM SPA (IT) | 2021-06-16 | — | — | EP | disclosed |
| US-9492410-B2 | Methods for treatment of Parkinson's disease | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2016-11-15 | — | — | US | disclosed |
| EP-2977046-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | Newron Pharmaceuticals S.p.A. (IT) | 2016-01-27 | — | — | EP | disclosed |
| US-5391577-A | Active on central nervous system; antiepileptic agents | FARMITALIA CARLO ERBA S R L (IT) | 1995-02-21 | — | — | US | disclosed |
| US-5236957-A | Antiepileptic agents | FARMITALIA CARLO ERBA SRL (IT) | 1993-08-17 | — | — | US | disclosed |
| EP-0426816-A1 | N-PHENYLALKYL SUBSTITUTED $g(a)-AMINO CARBOXAMIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | FARMITALIA CARLO ERBA S.r.l. (IT) | 1991-05-15 | — | — | EP | disclosed |
| WO-1990014334-A1 | N-PHENYLALKYL SUBSTITUTED α-AMINO CARBOXAMIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | FARMITALIA CARLO ERBA S.R.L. (IT) | 1990-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093495-A1 | Methods for treatment of parkinson's disease | MAOB, MAOA, SNCA | MAOB 1/4885MAOA 2/4885SCN9A 2416/4885 |
| US-20060079570-A1 | Alpha-aminoamide derivatives useful as antimigraine agents | AANAT, FAAH, ACHE | MAOB 184/4885MAOA 42/4885SCN9A 27/4885 |
| US-20100267835-A1 | Methods of treating disorders of trigeminalvascular activation | MVD, TBXA2R, BDKRB2 | MAOB 236/4885MAOA 283/4885SCN9A 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.